Journal
SMALL
Volume 7, Issue 5, Pages 625-633Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/smll.201002291
Keywords
-
Categories
Funding
- National Cancer Institute CCNE [U54 CA119367]
- In Vivo Cancer Molecular Imaging Centers ICMIC [P50 CA114747]
- Stanford Molecular Imaging Scholars Program SMIS [R25-T CA118681]
Ask authors/readers for more resources
The affibody functionalization of fluorescent surface-enhanced Raman scattering gold-silica nanoparticles as multimodal contrast agents for molecular imaging specific to epidermal growth factor receptor (EGFR) is reported. This nanoparticle bioconjugate reports EGFR-positive A431 tumors with a signal nearly 35-fold higher than EGFR-negative MDA-435S tumors. The low-level EGFR expression in adjacent healthy tissue is 7-fold lower than in the positive tumors. Validation via competitive inhibition reduces the signal by a factor of six, and independent measurement of EGFR via flow cytometry correlates at R-2 = 0.92.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available